5/22/2018 Aemetis: Solvency Concerns And An Upcoming Equity Offering - Aemetis, Inc. (NASDAQ:AMTX) | Seeking Alpha


https://seekingalpha.com/article/2409155-aemetis-solvency-concerns-and-an-upcoming-equity-offering 1/26


Aemetis: Solvency Concerns And An Upcoming Equity Offering
Aug. 11, 2014 9:30 AM ET31 comments
by: Richard Pearson


Summary


Aemetis now has over $90 million in short-term debts coming due, but only $4.7
million in cash. The company has already begun defaulting on its short-term debts.


This short-term nature is not reflected in the recent 10Q, due to an accounting
technicality that has been missed. More serious accounting issues may have also
been missed.


Creditors have already assumed as collateral ALL of Aemetis' assets, and are now
sweeping cash from Aemetis every night. Some creditors are attempting to seize
assets.


Aemetis recently filed a $100-million S3, and retained an investment bank to advise
on financing. A massive near-term equity offering is the only option for Aemetis.


With share price falling and no other options, the stock could enter a "death spiral"
and decline by 50%-80%. Past fraud charges for the CEO could exacerbate equity
discount.


(Editor's Note: Third Eye Capital disputes certain aspects of this article, and contests the
author's conclusions and calculations regarding the loans, the interest rate, the debt
service expenses, and the nature and implications of the cash sweep.)


Investment overview


Aemetis Inc. (NASDAQ:AMTX) is a company which is totally off the radar for most
investors. The company only recently uplisted to the Nasdaq from the OTC BB, and has
no institutional following. As a result, the mostly retail investor base has missed some
critical issues with the company.


Between May and July, shares of Aemetis rose from $5.00 to over $12.00. But now, the
shares have been dropping daily. Even though earnings on August 7th were relatively
positive, the shares have fallen by 20% since then, and are already down by more than
30% in just three weeks.



https://seekingalpha.com/symbol/AMTX
5/22/2018 Aemetis: Solvency Concerns And An Upcoming Equity Offering - Aemetis, Inc. (NASDAQ:AMTX) | Seeking Alpha


https://seekingalpha.com/article/2409155-aemetis-solvency-concerns-and-an-upcoming-equity-offering 2/26


The reason that the positive earnings did not cheer the stock is because Aemetis is very
deeply in debt and is already defaulting on obligations in both the US and India. Creditors
have already taken 100% of the cash generated by Aemetis this year, and are first in line
to take anything else that Aemetis can make. Indian creditors are already attempting to
seize assets.


It is clear that Aemetis must issue a massive amount of new stock to pay creditors, and it
must do so quickly. Aemetis has over $90 million in short-term debt coming due, and only
$4.7 million in cash.


Aemetis has already filed an S3 registration statement to raise up to $100 million, and has
engaged an investment bank to help with financing. The equity offering will put extreme
pressure on the share price. This is what is driving the share price down.


Because Aemetis MUST complete a financing regardless of price and because of the
urgency, the share price will continue to fall sharply. No one wants to be the last one
holding shares when the company conducts a huge equity offering.



http://www.sec.gov/Archives/edgar/data/738214/000135448814003900/amtx_10q.htm

http://www.sec.gov/Archives/edgar/data/738214/000135448814003556/amtx_s3.htm

https://static.seekingalpha.com/uploads/2014/8/10/4238561-14077053198250513-Richard-Pearson_origin.jpg
5/22/2018 Aemetis: Solvency Concerns And An Upcoming Equity Offering - Aemetis, Inc. (NASDAQ:AMTX) | Seeking Alpha


https://seekingalpha.com/article/2409155-aemetis-solvency-concerns-and-an-upcoming-equity-offering 3/26


The shares could fall by a further 50%-80% due to the "death spiral" nature of this
financing situation. Past examples will illustrate this problem clearly and why it applies to
Aemetis.


Again, the reason that the market has missed this is simply because:


a) Aemetis is an under-followed stock


b) Aemetis is mostly held by retail and has no legitimate research coverage


c) Aemetis only recently uplisted to the Nasdaq from the OTC BB


Background


In 2013, I wrote an article describing a "death spiral" at Biolase Inc. (NASDAQ:BIOL)
which saw the stock plunge by 80% in a week. The situation was very similar to what we
are starting to see now with Aemetis.


In early 2013, the Biolase share price was quite strong and traded as high as $6.00. In
August 2013, Biolase had just reported earnings and reported a very mild miss. It certainly
should not have been a big deal. But still, the share price plunged by 25% that day. The
death spiral had already begun... however, many investors had not yet realized it.


By the time I could finish my article within a few days, the stock had already fallen by 50%.
Despite this massive drop in less than a week, I still predicted even further declines. The
stock then fell an additional 30% on the day of my article alone.


With the stock down 80% in a week, Biolase took the unusual step of halting its own stock
when it hit $1.16, down from $3.60 before earnings. It was an epic plunge in just days, and
a far cry from $6.00 just weeks earlier.



https://seekingalpha.com/article/1634072-biolase-plunges-on-solvency-concerns

https://seekingalpha.com/symbol/BIOL

https://seekingalpha.com/article/1634072-biolase-plunges-on-solvency-concerns
5/22/2018 Aemetis: Solvency Concerns And An Upcoming Equity Offering - Aemetis, Inc. (NASDAQ:AMTX) | Seeking Alpha


https://seekingalpha.com/article/2409155-aemetis-solvency-concerns-and-an-upcoming-equity-offering 4/26


Biolase was ultimately able to stabilize and raise some of the money it needed. The stock
has recovered to around $2.00, still down by 45% from where it was before.


Biolase offers a good lesson in what triggers a death spiral. Biolase was in violation of its
loan covenants and needed to raise money urgently. Issuing stock was the only option,
and investors could plainly see that Biolase had filed a large S3 registration statement to
sell stock. The situation with Aemetis is nearly identical, except that Aemetis has far more
debt than Biolase.


In general, a death spiral will occur when a company needs to pay a fixed obligation (i.e.
debt) and when it must use a variable number of shares to do so. Investors know that the
stock will fall upon the equity offering, so they sell and the share price falls. But then, the
subsequent investors know that the equity offering has not yet happened, so they know
that the stock will continue to fall further. They sell, the stock falls, and the cycle repeats
again.


No one wants to get caught holding the stock, because it is pre-determined that it will
continue falling by even more. As the share price gets lower and lower, the relative dilution
becomes larger and larger, which then exacerbates the share price decline even more.



https://static.seekingalpha.com/uploads/2014/8/10/4238561-14077053519155326-Richard-Pearson_origin.jpg
5/22/2018 Aemetis: Solvency Concerns And An Upcoming Equity Offering - Aemetis, Inc. (NASDAQ:AMTX) | Seeking Alpha


https://seekingalpha.com/article/2409155-aemetis-solvency-concerns-and-an-upcoming-equity-offering 5/26


As with Biolase, Aemetis Inc. is now facing a death spiral situation, and for very
similar reasons. And as with Biolase, it is purely the fault of management for letting
the situation get to this point. More prudent management in years past could have
prevented this situation from arising.


Aemetis: Company Overview


Aemetis Inc. is a $200-million market cap producer of "alternative fuels". The company
produces biodiesel from a plant in India, and produces mainly ethanol from a plant in
California.


During Q1 of 2013, its ethanol plants were idled, as the company was experiencing
recurring negative gross margins. It was literally selling its product below cost, so it
decided to shut down. In recent quarters, the company has resumed operations, and a
buoyant market for ethanol has seen the company begin to eke out tiny profits in two
consecutive quarters. But it is still the case that over the past few years, the company has
accumulated over $80 million in cumulative losses.


Aemetis Inc. uplisted from the OTC BB to the Nasdaq in May, and its share price quickly
shot up from an initial price of $5.00 to over $12.00. One contributing factor was the strong
performance of any stock with an ethanol connection. For example, Pacific Ethanol
(NASDAQ:PEIX) is up by 400% in the past year. Aemetis has simply ridden on the
coattails of the sector.


The share price was also no doubt buoyed by a Seeking Alpha article entitled: "Aemetis Is
A Potential Four- Or Five-Bagger", as well as by the initiation of "research" on the
company by SeeThruEquity, which came with a $26 share price target.


See Thru claims (in all caps) that it does not get compensated to write such reports. But
instead, See Thru charges its clients $11,000 for slots at its conferences. It then issues
hyper-bullish research on the attendees "for free". As noted on the See Thru website,
Aemetis is an attendee in See Thru's conferences.


In reality, this is all just a very transparent way to pay for positive research on one's
own company.


Both the article and the research report contain materials which are largely a simple
repetition of company presentations, including links and direct quotes. As a result, they not
surprisingly portray the company in a very optimistic light, and contain multi-bagger share
price targets.



http://www.sec.gov/Archives/edgar/data/738214/000135448813002893/amtx_10q.htm

http://www.sec.gov/Archives/edgar/data/738214/000135448813000232/amtx_8k.htm

https://seekingalpha.com/symbol/PEIX

https://seekingalpha.com/article/2269273-aemetis-is-a-potential-four-or-five-bagger

http://moxreports.com/wp-content/uploads/AMTX-See-Thru-Equity.pdf

http://www.seethruequity.com/

http://moxreports.com/wp-content/uploads/AMTX-See-Thru-Equity.pdf

http://www.seethruequity.com/#!past-pcx/c1dm
5/22/2018 Aemetis: Solvency Concerns And An Upcoming Equity Offering - Aemetis, Inc. (NASDAQ:AMTX) | Seeking Alpha


https://seekingalpha.com/article/2409155-aemetis-solvency-concerns-and-an-upcoming-equity-offering 6/26


Yet, both of them ignore the obvious realities which are contained in Aemetis' SEC filings.
Even a quick and cursory read of the company filings reveals the following:


Aemetis already is and has been in default on its debts, with creditors already
attempting to seize assets.
The company has just $4.7 million in cash and over $95 million in short-term debt
coming due.
Over $65 million of this debt has been classified as "long term", simply because it is
due 1 day after the end of the quarter. As a result, that $65 million is all, in fact, short-
term debt by now.
Aemetis' major lender is already "sweeping" cash from the company every day, not
even trusting the company with cash overnight
The company's internal controls for accounting have been deemed to be ineffective.
Creditors have already claimed as collateral ALL of the assets of Aemetis
In order to avoid an immediate default, the CEO was forced to personally guarantee
$15 million of the debts with 100% of his own personal assets. If Aemetis defaults on
even this portion, he loses everything he owns - personally !


As a result of the above, Aemetis (and the CEO) are in the situation where they simply
MUST issue stock at any price and in very large size. They must also do so as soon as
possible.


The intention to issue equity should be clear. The company just filed an S3 registration
statement for up to $100 million. It is huge for a company of this size. The company also
disclosed that it has already "engaged an investment bank" to advise on its financing.


An equity offering is desperately needed, there are no alternatives, and the timing is
imminent. These are the precursors for a death spiral to occur. This is why the
stock has been selling off, even after earnings which were relatively good
(compared to the past). Yet, many of the retail holders will have no idea what is
coming.


The only reason why the equity offering hasn't already occurred is that the S3 is not
yet effective. This is also identical to what happened with Biolase. But just as with
Biolase, the S3 can become effective immediately and with no notice, such that an
equity offering could occur at any time.


How has the market missed this?



http://www.sec.gov/Archives/edgar/data/738214/000135448814003556/amtx_s3.htm
5/22/2018 Aemetis: Solvency Concerns And An Upcoming Equity Offering - Aemetis, Inc. (NASDAQ:AMTX) | Seeking Alpha


https://seekingalpha.com/article/2409155-aemetis-solvency-concerns-and-an-upcoming-equity-offering 7/26


The reason why this obvious situation has been missed by the market is that aside from
existing insiders, the stock is almost exclusively held by retail investors. There is no
institutional presence in terms of either investors or research. Because the stock was just
recently uplisted to the Nasdaq, it is largely unknown to the wider market.


Furthermore, there are many retail investors who simply invest based on company
descriptions who happen to be in hot sectors (i.e. ethanol).


The share price of Aemetis has no doubt benefited from the other soaring ethanol stocks,
such as Pacific Ethanol, which has been a stunning 5-bagger in the past year. Aemetis
CEO, Eric McAfee was an original founder of Pacific Ethanol, so some people choose to
associate the two together, even though Pacific happens to be a far healthier company.


How did Aemetis get into this situation?


In 2012, Aemetis sought to acquire a company called Cilion, but it didn't have the money.
As a solution, Aemetis went to a distressed lender by the name of Third Eye Capital. This
was really the beginning of the end for Aemetis.



https://static.seekingalpha.com/uploads/2014/8/10/4238561-14077054178314915-Richard-Pearson_origin.jpg
5/22/2018 Aemetis: Solvency Concerns And An Upcoming Equity Offering - Aemetis, Inc. (NASDAQ:AMTX) | Seeking Alpha


https://seekingalpha.com/article/2409155-aemetis-solvency-concerns-and-an-upcoming-equity-offering 8/26


In July 2012, Third Eye lent around $40 million to Aemetis by means of loans, notes and a
revolving credit facility. The "stated" interest rates have been as high as 17%, but due to a
creative variety of fees, the real rate of interest has approached 100% per year.


Aemetis clearly had no ability to repay these debts. In fact, it could not ever even service
the interest alone. Within less than 6 months, the company was already in default.


As a result, in October of 2012, Aemetis and Third Eye entered into Waiver and
Amendment #1. This extended the maturity of the obligations to July 2014 and increased
the lending amounts by $6 million.


But... the $6 million could not actually be drawn upon by Aemetis, it was simply extended
to account for the unpaid interest. For Aemetis, the only real result was that its debt
increased to $46 million instead of $40 million, with no new cash coming in the door.


Aemetis was just borrowing more money from Third Eye so that it could pay the money
directly back to Third Eye. Third Eye is doing nothing illegal here. This is how Third Eye
makes a fortune. In mafia movies, it's called "the vig".


But wait, it gets better.


In order to compensate Third Eye for this extension and waiver, Aemetis was required to
"pay" an additional "waiver fee" of $4 million. But again, Aemetis had no cash, so this was
just tacked on to the debt. So now the obligation became $50 million, instead of $40
million. And again, there was not even any new cash coming in the door at Aemetis.


The balance of the debt therefore increased by 25% in just 4 months!


That equates to an annualized rate of over 95%!


That was October, 2012. Within just 4 more months (February 2013), the company was
again in default. So Aemetis agreed to Waiver and Amendment #2.


This time, Aemetis was required to issue shares to pay an additional extension fee of $1.5
million. In addition, Third Eye required McAfee Capital to pledge millions of shares as
collateral. McAfee Capital is the investment company owned by Aemetis' CEO, Eric
McAfee, and which holds some of his shares.


That was the second default waiver within 8 months.


The third default and waiver happened just 3 more months later, with more waiver fees
and increased debt balances in respect of unpaid interest.



http://www.sec.gov/Archives/edgar/data/738214/000135448812005428/amtx_8k.htm

http://www.sec.gov/Archives/edgar/data/738214/000135448813001112/amtx_8k.htm

http://www.sec.gov/Archives/edgar/data/738214/000135448813002039/amtx_ex101.htm
5/22/2018 Aemetis: Solvency Concerns And An Upcoming Equity Offering - Aemetis, Inc. (NASDAQ:AMTX) | Seeking Alpha


https://seekingalpha.com/article/2409155-aemetis-solvency-concerns-and-an-upcoming-equity-offering 9/26


Then, there was a fourth default and waiver. And a fifth. And a sixth. And a seventh.


At each new waiver just a few months apart, Third Eye would impose additional fees and
would jack up the interest rates. The net result was that by late 2013 (less than 18
months), Aemetis' debt to Third Eye had ballooned to over $72 million from just $40
million.


The "vig" was quickly compounding at a truly unsustainable rate.


By the end of 2013 (within 18 months), total annual debt service amounts were accruing
and almost $30 million per year - and this for a debt that started at just $40 million.


But Third Eye still wasn't satisfied, and was repeatedly demanding warrants. Aemetis was
already in default. If Aemetis attempted to say no, Third Eye could just foreclose on the
assets of the entire company. Third Eye could now call all of the shots.


As a result of the heavy warrants and shares being issued, Third Eye quickly owned
over 17% of the entire company!


But at the current valuation, Third Eye's equity stake is worth just $34 million - only half of
what it has lent to Aemetis. And the problem now is that Aemetis has demonstrated a very
limited capacity to pay down these debts.


As a result, Third Eye is now agitating for the equity offering. In one default waiver
amendment, Aemetis agreed to give Third Eye 100% of the proceeds of any equity
offering it conducts in excess of $7 million. This is how Third Eye plans to get its money
back.


The stock will clearly be crushed and Aemetis will end up getting almost none of the
proceeds, but Third Eye will get its incredible pound of flesh out of the deal after just 2
years.


What happened with earnings? Why is the stock falling?


Last Thursday, Aemetis reported Q2 earnings, and the numbers appeared good on the
surface. But the share price quickly fell by 10% that day, and continued its descent on
Friday. This is just what we saw with Biolase.


In the press release, the company noted the following:


Revenues increased 21% vs. Q2 2013
Net income was $2.7 million, compared to a loss of $9 .6 million in Q2 2013



http://www.sec.gov/Archives/edgar/data/738214/000135448813004149/amtx_ex101.htm

http://www.sec.gov/Archives/edgar/data/738214/000135448813005962/amtx_ex101.htm

http://www.sec.gov/Archives/edgar/data/738214/000135448814001121/amtx_10k.htm
5/22/2018 Aemetis: Solvency Concerns And An Upcoming Equity Offering - Aemetis, Inc. (NASDAQ:AMTX) | Seeking Alpha


https://seekingalpha.com/article/2409155-aemetis-solvency-concerns-and-an-upcoming-equity-offering 10/26


Aemetis paid down $13.6 million of debt (interest and principal)


These all would appear to be very positive developments. As such, retail investors were
likely confused by the sharp drop in the stock.


More savvy investors quickly realized that positive comparisons to 2013 are unfair,
because the plant had been idled for almost a month during Q2 2013. Had it not been
idled, revenues would have come out as being largely flat, despite a very buoyant ethanol
market in 2014.


In reality, the results are actually a bit of a disappointment.


As for the debt, a closer read of the subsequently released 10Q reveals that debt service
expenses are still accruing at over $5 million per quarter (a run rate of over $20 million per
year). In addition, every penny of cash generated by Aemetis has already been handed
over to creditors, mostly to Third Eye.


But even after handing every penny of cash that came in the door, Aemetis still has
over $95 million in short-term liabilities coming due. Aemetis has made virtually no
progress whatsoever, even in the best ethanol market in a decade.


Note: Many investors could have easily missed the short-term nature of $65 million these
liabilities, because in the Form 10Q, they are classified as "long-term liabilities". The
reason for this classification is that Aemetis agreed with Third Eye to set the new maturity
date as July 1, one day after Q2 ends. As a result, they were technically considered to be
"long-term" obligations in the most recent 10Q - but only by a single day. These
obligations are now clearly short-term liabilities.


For those who care about accounting ratios, Aemetis has a stated "current ratio" of 0.4.
That should already be extremely concerning. Anything below 1.0 indicates meaningful
financial weakness. Anything below 0.5 indicates a severe liquidity issue.


But in fact, it is much worse. Because all of these liabilities are now short term, the
real current ratio for Aemetis is just 0.1. The company is visibly insolvent.


What about "alternative" financing sources?


California Energy Commission Grant


In late July, Aemetis put out a press release stating that "Aemetis announces $3M CEC
grant award". Even though $3 million is not enough to move the needle vs. over $90
million in upcoming debts, the $3 million would serve as a small amount of welcome relief.



http://finance.yahoo.com/news/aemetis-announces-3-million-cec-124500649.html
5/22/2018 Aemetis: Solvency Concerns And An Upcoming Equity Offering - Aemetis, Inc. (NASDAQ:AMTX) | Seeking Alpha


https://seekingalpha.com/article/2409155-aemetis-solvency-concerns-and-an-upcoming-equity-offering 11/26


However, it appears that investors may have assumed that this money was already
distributed to Aemetis. This is wrong.


There are several problems here. First, the grant is still contingent upon approval of the
project. It has not even been distributed. Second, the grant is a matching grant, which
means that Aemetis itself must put up $3 million in order to receive the grant. But Aemetis
only has $4.7 million in cash total. Third (and most importantly), as part of one of the
default waivers, Aemetis already agreed that any proceeds from grants would go straight
to Third Eye. Aemetis will see none of the money from this grant.


California Ethanol Producer Incentive Program.


Aemetis is eligible to participate in this California program, which subsidizes ethanol
producers in times when crush spreads are too low to make money.


Unfortunately, the program also requires ethanol producers to repay the funds when
times improve. Because times are good for ethanol right now, Aemetis actually owes
money to this program.


As a result of this, Aemetis noted in the most recent 10Q that:


During the six months ended June 30, 2014, the strength of the crush spread
resulted in the accrual and obligation to repay CEPIP funding in the amount of
$1.8 million, the entire remaining amount of funds received from the program.


This is in addition to the other debts listed for Aemetis.


EB-5 Visa program


This is an odd one. In an attempt to obtain funding, Aemetis enrolled in a program by
which it can effectively sell US immigration visas to foreigners. Foreigners can "invest"
$500,000 each into notes issued by Aemetis. Because they are investing in a US business
and presumably creating jobs, the foreigner then gets a US immigration visa.


The notes can be converted into Aemetis stock at a price of $3.00 - but only after 3 years.


Even though this appears to be a great deal (getting stock at $3.00), Aemetis has only
managed to sell 3 of these visa investments since 2012, raising just $1.5 million. The
reason that there has been no demand is that investors need to wait for 3 years in order to
get their stock. These investors will know that they come behind over $90 million in debt,
5/22/2018 Aemetis: Solvency Concerns And An Upcoming Equity Offering - Aemetis, Inc. (NASDAQ:AMTX) | Seeking Alpha


https://seekingalpha.com/article/2409155-aemetis-solvency-concerns-and-an-upcoming-equity-offering 12/26


such that there is a very real chance that they may never get paid. In fact, in 2013,
Aemetis was not even paying the owed interest to these investors who paid their
$500,000 each. Not surprisingly, selling more of these has been difficult.


Despite only selling 3 of these in the past 2 Â½ years, Aemetis continues to state that this is
a source of funding which they hope to rely upon.


But once again (and of greatest importance), Third Eye has already laid claim to any
potential proceeds from this source. In Default Waiver #5, Third Eye forced Aemetis
to agree to remit any proceeds from EB-5 sales to Third Eye.


Loans from board members


In the recent past, CEO Eric McAfee has already forgone actual cash payment of his
salary and benefits, because Aemetis is unable to pay. Aemetis simply accrues these
expenses along with the other debts which it is not paying. But because 100% of his
personal assets have been claimed by Third Eye as collateral, Mr. McAfee is no longer
able to extend any form of credit to Aemetis.


As early as 2009, board member Laird Cagan extended $5 million of credit to Aemetis,
which was secured by assets of the company. But as usual, the company was unable to
even pay the interest. As a result, the company issued stock to Mr. Cagan in exchange for
the $5-million debt. As a result of this, Mr. Cagan ended up quickly owning 12% of the
entire company, which he acquired at just 45 cents per share.


This once again demonstrates what we are about to see: when the company has debts
which it cannot pay, and when issuing stock is the only option, the price at which stock can
be issued tends to be very, very low. Aemetis will truly issue stock at any price, because it
has no other options.


Complications for an equity offering - accounting issues


I was an investment banker on Wall Street for nearly a decade. I helped many troubled
companies raise money when the situation looked very desperate. One thing I learned is
that there is almost always a price at which a deal can get done.


I do believe that Aemetis will be able to complete some amount of financing to stave off
insolvency. But it is also clear that the price at which a deal gets done for Aemetis will be
very, very low.



http://www.sec.gov/Archives/edgar/data/738214/000135448813004149/amtx_ex101.htm

http://www.sec.gov/Archives/edgar/data/738214/000135448813002203/amtx_ex101.htm
5/22/2018 Aemetis: Solvency Concerns And An Upcoming Equity Offering - Aemetis, Inc. (NASDAQ:AMTX) | Seeking Alpha


https://seekingalpha.com/article/2409155-aemetis-solvency-concerns-and-an-upcoming-equity-offering 13/26


We already know that nearly all proceeds of the offering will simply be handed to Third
Eye. This is already a problem for potential investors, because they know that a financing
will not go to improve the business or increases capacity. The financing itself does nothing
for Aemetis and everything for Third Eye.


But, in fact, there is a much larger problem looming for Aemetis.


Aemetis may have additional accounting problems. which could require an even
bigger discount from anyone who might choose to finance the company.


In its annual 10K filed in March, Aemetis noted that:


We have identified material weaknesses in our internal control over financial
reporting which have materially adversely affected our ability to timely and
accurately report our results of operations and financial condition. These
material weaknesses have not been fully remediated as of the filing date of
this report.


The deficiencies in internal control were not minor, in fact, they were very significant.


The 10K (p. 28) explained that there may be significant problems with the numbers, most
importantly, including cash flow numbers.


The material weaknesses identified are: Ineffective controls exist to ensure that the
accounting and reporting for complex accounting transactions are recorded in
accordance with GAAP. A number of significant audit adjustments were made to
the general ledger, which collectively could have a material effect on the financial
statements. These adjustments were made up of entries to properly record the
carrying value of debt issue costs, warrant accounting and various other
adjustments summarized in our Report to the Audit Committee communication.


As part of our review of the financial statements included in the 10-K, we also made
significant revisions to the statement of cash flows and various notes to the
financial statements, which indicate that additional controls over disclosures need
to be evaluated.


The company also noted that it was making efforts to remediate these problems.


But here is where it becomes much more problematic.
5/22/2018 Aemetis: Solvency Concerns And An Upcoming Equity Offering - Aemetis, Inc. (NASDAQ:AMTX) | Seeking Alpha


https://seekingalpha.com/article/2409155-aemetis-solvency-concerns-and-an-upcoming-equity-offering 14/26


A few weeks later, when Q1 was reported, Aemetis noted that


There were no changes in our internal controls over financial reporting during our
most recently completed fiscal quarter that have materially affected, or are
reasonably likely to materially affect, our internal control over financial reporting.


Despite the "no changes", Aemetis management is now saying that the previously
disclosed problems no longer matter.


On page 30 of the Q1 10Q and on page 35 of the Q2 10Q, it is noted that:


Our controls and procedures are designed to provide reasonable assurance that our
control system's objective will be met and our CEO and CFO have concluded that
our disclosure controls and procedures are effective at the reasonable
assurance level.


Something is quite wrong here.


When a company discloses serious deficiencies in its accounting controls in one quarter
and then says that no changes have been made, it is not possible to suddenly say that the
numbers, including cash flow, are all just fine. Yet, this is what Aemetis has done.


The fact that these problems are being swept under the rug at just the time that the
company is looking to complete a large equity offering makes the problem that much
worse.


This is clearly something that small retail investors will miss, but larger investors who
might finance the company will spot immediately. To the extent that they have any
concerns over the accuracy of the accounting numbers, they will definitely require a
steeper discount on the equity price.


Past 10b5 fraud charges against the CEO, Eric McAfee, will not help that matter
either.


In a previous OTC BB oil and gas company, Verdisys, Mr. McAfee was also the largest
shareholder and CEO.


According to the SEC, McAfee duped the company's board into buying useless software
from a different company which he controlled. He then diverted that money to a stock
promoter to promote the stock.



http://www.sec.gov/Archives/edgar/data/738214/000135448814002701/amxt_10q.htm
5/22/2018 Aemetis: Solvency Concerns And An Upcoming Equity Offering - Aemetis, Inc. (NASDAQ:AMTX) | Seeking Alpha


https://seekingalpha.com/article/2409155-aemetis-solvency-concerns-and-an-upcoming-equity-offering 15/26


McAfee then fabricated a large receivable from a supposed customer, and forced the
accounting department to put out the 10Q filing without letting the auditor review it. The
auditor had already raised revenue recognition issues with the transaction. He did all of
this in order to prevent the share price from falling.


This is all pretty bad stuff. As a result, Mr. McAfee was sanctioned for fraud violations, and
cease and desist orders were issued.


Here is what happened, according to fraud proceedings with the SEC:



https://www.sec.gov/litigation/admin/2006/34-54234.pdf
5/22/2018 Aemetis: Solvency Concerns And An Upcoming Equity Offering - Aemetis, Inc. (NASDAQ:AMTX) | Seeking Alpha


https://seekingalpha.com/article/2409155-aemetis-solvency-concerns-and-an-upcoming-equity-offering 16/26


Verdisys issued two million shares of common stock, valued at $1 million,
ostensibly to acquire software, but that the software had been deemed not
useful, and Verdisys was therefore recording an impairment expense of $1 million.


McAfee had convinced the Verdisys board to purchase the software by claiming it
would allow the remote monitoring of oil and gas wells, which would complement
Verdisys' sales of broadband satellite links to oil and gas companies. McAfee
controlled the company selling the software, and he knew that the software only
screened job applications and resumes of health care executives and did not
monitor conditions in oil and gas wells. McAfee did not tell the company's
directors that the transaction compensated a stock promoter, who received half of
the two million shares.


As a result, McAfee caused Verdisys, essentially a start-up company, to not disclose
that it had issued one million shares and incurred a compensation expense of
$500,000, to retain the promoter, before it could claim significant assets, revenues
or business operations.


Verdisys delayed the filing of its quarterly report for the quarter ended September 30,
2003 (the "3Q Form 10-QSB"), after its auditor raised revenue recognition issues
concerning a material $1.5 million receivable related to the company's largest
drilling contract. While the filing was in abeyance, McAfee caused Verdisys to issue
an earnings release predicting the company would soon report record earnings.


McAfee participated in efforts to justify recognition of the $1.5 million receivable. On
November 19, 2003, to meet the filing deadline and avoid any drop in the
company's stock price, McAfee ordered Verdisys' accounting staff to file the
3Q Form 10-QSB, even though the auditor had yet to review the financial
statements found in the filing. The 3Q Form 10-QSB filed as a result claimed
Verdisys had earned total current period revenues of $2.09 million, including the
questioned $1.5 million receivable. The 3Q Form 10-QSB did not disclose that
McAfee's attempts to confirm recognition of the $1.5 million receivable involved a
buy-out agreement, by which Verdisys would assume substantial liabilities and
forego collecting upon the $1.5 million receivable to purchase the drilling project
from which the receivable arose.


As a result of the conduct described above, McAfee caused Verdisys to violate
Section 10(b) of the Exchange Act and Rule 10b-5 thereunder, which prohibit
fraudulent conduct in connection with the purchase or sale of securities.
5/22/2018 Aemetis: Solvency Concerns And An Upcoming Equity Offering - Aemetis, Inc. (NASDAQ:AMTX) | Seeking Alpha


https://seekingalpha.com/article/2409155-aemetis-solvency-concerns-and-an-upcoming-equity-offering 17/26


Ultimately, McAfee settled with the SEC, paid a fine and moved on to other projects.
Verdisys later changed its name to Blast Energy, and is no longer listed.


I don't expect that any retail investors have conducted this level of research in evaluating
their investment in Aemetis. But it should be expected that investors who might choose to
participate in an offering of up to $100 million will focus quite clearly on this history.


The fact that Aemetis recently disclosed its internal accounting problems and then
quickly covered them up just in time for a financing will certainly be noticed, and
will be another factor which will require a steep discount in selling new equity.


It will not be lost on the investors that absolutely all of Mr. McAfee's personal assets
have been pledged to secure the loans of Aemetis. If the Aemetis creditors choose
to foreclose, they will take everything he has. As a result, there is a very high
amount of pressure on Mr. McAfee to get an equity deal done and to perhaps
conveniently overlook the accounting problems which might interfere with getting
his personal assets back under his own control and out of the clutches of Third
Eye.


Please note: I did attempt to contact Aemetis by phone for comment and clarification on
these issues, but my calls have not yet been returned.


Conclusion


Right now, there are very strong tailwinds boosting alt energy stocks such as biodiesel
and ethanol plays. This can be clearly seen by looking at the soaring share prices of
stocks such as Pacific Ethanol.


But unfortunately, the dire straits in which Aemetis has landed basically ensure that no
amount of tailwind is going to benefit Aemetis shareholders. For any amount of cash that
comes in, Third Eye Capital stands ready to confiscate it. Third Eye is already "sweeping"
cash from Aemetis every night. That applies to cash from biodiesel and ethanol sales,
from grants and subsidies and even from Aemetis' unusual US visa selling program. Third
Eye and the lenders take everything.


Aemetis has over $90 million in near-term debts, and just $4.7 million in cash with which
to repay it. But as of the last 10Q, much of this was technically referred to as "long-term"
debt. There is no mistake that this is currently short-term debt now.
5/22/2018 Aemetis: Solvency Concerns And An Upcoming Equity Offering - Aemetis, Inc. (NASDAQ:AMTX) | Seeking Alpha


https://seekingalpha.com/article/2409155-aemetis-solvency-concerns-and-an-upcoming-equity-offering 18/26


Aemetis has already defaulted on loans, and its Indian creditors have already begun
attempting to accelerate the seizure of assets. Each time a default is waived for a few
months only adds massive new debt burdens to the company in the form of waiver fees,
penalties and new interest. The "vig" is compounding at an unsustainable rate.


But now the burden is getting so high that Aemetis risks collapse, and now Third Eye
finally needs to convert these debts into cash.


Aemetis has filed a $100 million S3 in order to sell equity, and has engaged an investment
banker to advise on financing. As a result, the share price has already fallen quickly by
30% in 3 weeks.


But now that the financing becomes more visible, the share price decline is likely to
accelerate. No one wants to be left holding the stock when all of the other buyers
disappear ahead of the offering. This is just what we saw with Biolase last year, when the
stock plunged by 80% in a single week.


Concerns over accounting issues and internal controls will likely mean that the discount
required in an equity offering is even deeper than might otherwise be the case. Investors
will want to know why Aemetis is now ignoring the accounting problems just revealed in
March, and why they are being ignored right ahead of a must-complete equity offering.
The past history of similar fraud by the CEO will certainly not help this issue with investors.


Based on these issues, a quick drop of 50%-80% in the share price is now entirely
predictable.


Disclosure: The author is short AMTX. The author wrote this article themselves, and it
expresses their own opinions. The author is not receiving compensation for it. The author
has no business relationship with any company whose stock is mentioned in this article.


Additional disclosure: The author was previously an investment banker for a major
global investment bank and was engaged in investment banking transactions with variety
of alternative energy companies. The author has not been engaged in any investment
banking transactions with US listed companies during the past 5 years. The author is not a
registered financial advisor and does not purport to provide investment advice regarding
decisions to buy, sell or hold any security. The author currently holds a short interest in
AMTX and has provided fundamental and/or technical research to investors who hold a
short position. The author may choose to transact in securities of one or more companies
mentioned within this article within the next 72 hours. Before making any decision to buy,
sell or hold any security mentioned in this article, investors should consult with their
5/22/2018 Aemetis: Solvency Concerns And An Upcoming Equity Offering - Aemetis, Inc. (NASDAQ:AMTX) | Seeking Alpha


https://seekingalpha.com/article/2409155-aemetis-solvency-concerns-and-an-upcoming-equity-offering 19/26


